ABBV · Earnings call · 2026Q3T · Full report

Juvmo Parkinson’s Market Launch

AbbVie Inc. · 2026-10-30 · Importance 40 · Surprise 42

AbbVie began launching Juvmo, an FDA-approved Parkinson's treatment that selectively activates D1/D5 dopamine receptors and can be used alone or added to standard care. Management described its motor-control profile and low rates of certain debilitating side effects as differentiating it from available dopamine agonists, which primarily target D2/D3 receptors. Sales are expected to ramp gradually while commercial and Medicare coverage is established, with broader Medicare availability expected starting in 2028.

Key facts

• The FDA approved AbbVie's Juvmo for Parkinson's disease.
• AbbVie expects Juvmo sales to ramp gradually over the next several quarters, with broader Medicare coverage expected starting in 2028.
• AbbVie said the Juvmo growth contribution will be more significant in 2028 and beyond because of the timing of Medicare coverage.
• After more than 1.5 years on Juvmo, 93% of patients had not increased their levodopa dose, and 94% of patients with early Parkinson's disease had not started oral levodopa.